AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02167048
Drug: Psychostimulants
RxNorm normalized name: Other psychostimulants and nootropics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).~To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions.
Trial: NCT03337932
Drug: Doxycycline 100 milligram Oral Tablet bid, 7 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive doxycycline for 7 days.
Trial: NCT03337932
Drug: Doxycycline 100 milligram Oral Tablet bid, 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive doxycycline for 14 days.
Trial: NCT03337932
Drug: Controls without a history of lyme disease.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No intervention.
Trial: NCT02484638
Drug: CSL689
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
Trial: NCT06311448
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care during COVID-19 pandemic including steroids.
Trial: NCT00123461
Drug: Hectorol (doxercalciferol capsules), 0.5mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02214862
Drug: [F18]-FDDNP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: radiopharmaceutical tracer
Trial: NCT02176460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet twice daily
Trial: NCT00714688
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2xplacebo once daily for 13 weeks
Trial: NCT01540019
Drug: Paullinia cupana
RxNorm normalized name: Paullinia cupana seed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg of Paullinia cupana as capsule, twice daily
Trial: NCT01991678
Drug: 145 mg/m2 NKTR 102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01991678
Drug: 120 mg/m2 NKTR 102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01991678
Drug: 50 mg/m2 NKTR 102
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02077556
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
Trial: NCT00409500
Drug: AQW051
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04150068
Drug: Failing ARV Regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Failing antiretroviral (ARV) regimen defined by the lack of efficacy. Any combination of approved and unapproved agents that could potentially be part of the failing regimen.
Trial: NCT04150068
Drug: Optimized Background Regimen (OBR)
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optimized background regimen as prescribed by the Investigator
Trial: NCT01853696
Drug: prednisolone acetate 1%
RxNorm normalized name: PREDNISOLONE ACETATE 1% SUSP,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04521114
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo will be administered subcutaneously every week for 13 weeks.
Trial: NCT00913224
Drug: Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)
RxNorm normalized name: diclofenac sodium 50 MG
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00772187
Drug: intrathecal analgesia (morphine)
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.1-0.5 mg of morphine
Trial: NCT00772187
Drug: general anesthesia (fentanyl)
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: general anesthesia alone
Trial: NCT00438256
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally starting on day one of radiation therapy for 2 weeks
Trial: NCT01846468
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules
Trial: NCT00798018
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
Trial: NCT00798018
Drug: N.S
RxNorm normalized name: INTRAPERITONEAL ADMIN.SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
Trial: NCT00354042
Drug: GW597901X
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01709071
Drug: Middle dose Sabin-IPV
RxNorm normalized name: Juniperus sabina leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01709071
Drug: Middle dose adjuvanted Sabin-IPV
RxNorm normalized name: Juniperus sabina leaf
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00771979
Drug: AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
Trial: NCT02563522
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care plus placebo
Trial: NCT00771979
Drug: AZD0530
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
Trial: NCT02294461
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT01065714
Drug: Eucerin Lotion
RxNorm normalized name: EUCERIN LOTION,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
Trial: NCT00003934
Drug: tretinoin
RxNorm normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT00003934
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00003934
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02738229
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00612716
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
Trial: NCT00002761
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00371696
Drug: diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00323024
Drug: NX1011
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02943785
Drug: VKA-based Regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
Trial: NCT03124355
Drug: placebo sugar pill
RxNorm normalized name: placebo Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo single oral dose
Trial: NCT00214734
Drug: rAHF-PFM
RxNorm normalized name: Advate rAHF-PFM
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02415335
Drug: Isotonic NaCl
RxNorm normalized name: ISOTON
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenously administration minimum of 30 minutes preoperatively
Trial: NCT00905268
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
Trial: NCT01743118
Drug: SPS4251 Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
Trial: NCT01743118
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
Trial: NCT01743118
Drug: Daivonex® ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
Trial: NCT01207115
Drug: ABT-652
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
Trial: NCT01207115
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules - twice daily for 8 weeks
Trial: NCT01207115
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen capsules - twice daily for 8 weeks
Trial: NCT00960284
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given orally
Trial: NCT00960284
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01020487
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules taken with water
Trial: NCT02801526
Drug: CKD-330 16/5mg - A
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00586508
Drug: Non-enzyme inducing antiepileptic drugs (NEIAED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT00518310
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00518310
Drug: AZAPRED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
Trial: NCT02431806
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched over-encapsulated placebo capsules administered orally on Day 1 to Week 8.
Trial: NCT02431806
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-encapsulated fluoxetine tablets administered orally on Day 1 to Week 8.
Trial: NCT01093690
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
Trial: NCT01926197
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 400 mg/m² IV over 2 hours on Day 1 of a 14-day cycle.
Trial: NCT01926197
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5FU 2,400 mg/m² IV over 46 to 48 hours starting on Day 1 of a 14-day cycle.
Trial: NCT00889187
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00512473
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9 % NaCl
Trial: NCT01686256
Drug: Tc 99m EC20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
Trial: NCT03205345
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo
Trial: NCT00234832
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
Trial: NCT01234675
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg twice daily
Trial: NCT00525642
Drug: Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
Trial: NCT00525642
Drug: Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
Trial: NCT04006652
Drug: ApoGraft
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ApoGraft is a cell based product, manufactured with mobilized peripheral blood.
Trial: NCT03017131
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01799993
Drug: Amikacin Inhalation Solution (BAY41-6551)
RxNorm normalized name: amikacin Inhalation Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
Trial: NCT01799993
Drug: Aerosolized Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
Trial: NCT01333956
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
Trial: NCT00410462
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02655419
Drug: ATM-AVI
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cohort 1:~(Creatinine clearance \> 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI~Cohorts 2 and 3:~(Creatinine clearance \> 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI~(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:~4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI
Trial: NCT03149887
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
Trial: NCT00501111
Drug: AZD3480
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 oral doses
Trial: NCT02620384
Drug: Experimental: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
Trial: NCT01657071
Drug: YH14659
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH14659 capsule by oral
Trial: NCT03838406
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX :~Day 1: Oxaliplatin 85mg/m2 IV + leucovorin 400mg/m2 IV + Fluorouracil (5-FU) 400mg/m2 IV Days 1 and 2: 5-FU 1200mg/m2 IV continuous infusion over 24 hours daily. Repeat cycle every 14 days.~CAPOX:~Day 1: Oxaliplatin 130mg/m2 IV Days 1-14: Capecitabine 1000mg/m2 orally twice daily. Repeat cycle every 21 days.
Trial: NCT01900431
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
Trial: NCT01900431
Drug: Folic/folinic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
Trial: NCT01704001
Drug: ART-123
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
Trial: NCT03403621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active ingredient. Approximately 1.8 mL single dose delivered as topical silicone compounding base only.
Trial: NCT00932386
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline infusing
Trial: NCT03239171
Drug: Life information rehabilitation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each treatment: one bottle solution each day, consecutive 3 months, oral administration
Trial: NCT01828476
Drug: ABT-263
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
Trial: NCT01229813
Drug: low dose capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 500 mg twice daily
Trial: NCT00727987
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
Trial: NCT00727987
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
Trial: NCT01196936
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet daily
Trial: NCT00711776
Drug: Current formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Current formulation of Aciclovir Cream 5% in Japan
Trial: NCT04950790
Drug: Basic treatment
RxNorm normalized name: Basic Fuchsin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Give oral aspirin enteric soluble tablets 150-300mg/d as early as possible after the onset of the disease, which can be changed to a prophylactic dose (50-325mg/d) after the acute phase. For those who cannot tolerate For those who cannot tolerate aspirin, clopidogrel can be used.
Trial: NCT02638129
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone HCl/bupropion HCl placebo-matching tablets
Trial: NCT04950790
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterilized water for injection，5ml/ injection, intravenous infusion, 20ml each time, once a day, diluted 250ml with normal saline, 15-30 drops/min.
Trial: NCT00156975
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01876719
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02153697
Drug: Pigmanorm Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
Trial: NCT03159845
Drug: Zinc Sulfate Oral Product
RxNorm normalized name: zinc sulfate Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01100372
Drug: liposome-encapsulated doxorubicin citrate
RxNorm normalized name: liposomal encapsulated paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01601821
Drug: CsA+Rapamune+CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
Trial: NCT01601821
Drug: CsA+MMF+CS
RxNorm normalized name: MyoGesic-CS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control arm is the standard local practice (official protocol) in Iran:~Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS.
Trial: NCT00266136
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: see protocol